ClinicalTrials.gg

Program

avacincaptad pegol

Also written as “Avacincaptad Pegol”, “Izervay™” and “Zimura”.

Its studies are mostly in Geographic Atrophy · Macular Degeneration · Polypoidal Choroidal Vasculopathy · Stargardt Disease, led by 2 companies.

Furthest: phase 4, since May 6, 202511 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma101 open or runningphase 4since May 6, 2025Jul 1, 2008Jun 30, 2027phase 4 · NCT06970665
Hoffmann-La Roche10 open or runningphase 1since Apr 29, 2025Apr 29, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2008First study: phase 1 study in Neovascular Age-Related Macular DegenerationNew to Astellas PharmaAstellas Pharma · NCT00709527 · 60 enrolled · United States
  2. Jul 30, 2009Phase 1 study in Dry Age-Related Macular DegenerationAstellas Pharma · NCT00950638 · 47 enrolled · United States
  3. Mar 19, 2015Phase 2 study in Polypoidal Choroidal VasculopathyAstellas Pharma · NCT02397954 · 4 enrolled · United States
  4. Feb 16, 2016Phase 3 study in Geographic AtrophyAstellas Pharma · NCT02686658 · 286 enrolled · United States, Croatia, Czechia and more
  5. Oct 30, 2017Phase 2 study in Neovascular Age-related Macular DegenerationAstellas Pharma · NCT03362190 · 64 enrolled · United States, Hungary, Latvia
  6. Dec 1, 20172 phase 2 studiesAstellas Pharma · NCT03364153, NCT03374670
  7. May 12, 2020Phase 3 study in Geographic AtrophyAstellas Pharma · NCT04435366 · 448 enrolled · United States, Argentina, Australia and more
  8. Sep 7, 2022Phase 3 study in Geographic AtrophyAstellas Pharma · NCT05536297 · 278 enrolled · United States, Argentina, Australia and more
  9. Apr 29, 2025Hoffmann-La Roche's first study: phase 1 study in Geographic AtrophyNew to Hoffmann-La RocheHoffmann-La Roche · NCT06961370 · 27 enrolled · United States
  10. May 6, 2025Phase 4 study in Geographic AtrophyAstellas Pharma · NCT06970665 · 17 enrolled · Japan

Ahead

  1. Jun 30, 2027Primary completion: phase 4 study in Geographic AtrophyAstellas Pharma · NCT06970665

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06970665Geographic Atrophy · Japan4Active, not recruitingAstellas PharmaJun 30, 202717
NCT06961370Geographic Atrophy · United States1TerminatedHoffmann-La RocheFeb 3, 202627
NCT05536297Geographic Atrophy · United States, Argentina, Australia and more3CompletedAstellas PharmaApr 10, 2025278
NCT04435366Geographic Atrophy · United States, Argentina, Australia and more3CompletedAstellas PharmaJul 25, 2022448
NCT03374670Polypoidal Choroidal Vasculopathy · United States2WithdrawnAstellas PharmaDec 20190
NCT03364153Stargardt Disease · United States, France, Germany and more2CompletedAstellas PharmaMar 31, 2025121
NCT03362190Neovascular Age-related Macular Degeneration · United States, Hungary, Latvia2CompletedAstellas PharmaOct 18, 201864
NCT02686658Geographic Atrophy · United States, Croatia, Czechia and more3CompletedAstellas PharmaSep 26, 2019286
NCT02397954Polypoidal Choroidal Vasculopathy · United States2CompletedAstellas PharmaOct 23, 20154
NCT00950638Dry Age-Related Macular Degeneration · United States1CompletedAstellas PharmaMar 24, 201147
NCT00709527Neovascular Age-Related Macular Degeneration · United States1CompletedAstellas PharmaDec 30, 200960

How it is read

Names in the registry

  • “Avacincaptad Pegol”, 6 entries
  • “avacincaptad pegol”, 3 entries
  • “Izervay™”, 1 entry
  • “Zimura”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.